Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 7/20 | 0.47 |
| ▸ | GIPR | P48546 | 3/20 | 0.47 |
| ▸ | GCG | P01275 | 9/20 | 0.45 |
| ▸ | GLP1R | P43220 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087311 | 0.81 | GCGR (0.44) | GCGRGIPRGCGGLP1R | |
| SCHEMBL4095211 | 0.79 | GCGR (0.53) | GCGRGIPRGLP1REPHX2DHODH | |
| SCHEMBL2650834 | 0.79 | GCG (0.52) | GCGRGIPRGCGGLP1REPHX2 | |
| SCHEMBL6189133 | 0.79 | GCGR (0.54) | GCGRGIPRGCGGLP1REPHX2 | |
| SCHEMBL4081867 | 0.78 | GCG (0.51) | GCGRGIPRGCGGLP1REPHX2 | |
| SCHEMBL4081870 | 0.78 | GCG (0.51) | GCGRGIPRGCGGLP1REPHX2 | |
| SCHEMBL2662982 | 0.76 | GCGR (0.70) | GCGRGIPRGLP1R | |
| SCHEMBL2661778 | 0.76 | GCG (0.49) | GCGRGIPRGCGGLP1REPHX2 | |
| SCHEMBL4094144 | 0.76 | GCGR (0.55) | GCGRGIPRGCGGLP1REPHX2 | |
| SCHEMBL4082147 | 0.74 | GCGR (0.63) | GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GCG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.